Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
13,253
archived clinical trials in
Arthritis

A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
mi
from
Decatur, GA
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
mi
from
Decatur, GA
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
mi
from
Coeur D Alene, ID
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
mi
from
Coeur D Alene, ID
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
mi
from
Park Ridge, IL
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
mi
from
Park Ridge, IL
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
mi
from
Bettendorf, IA
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
mi
from
Bettendorf, IA
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
mi
from
Overland Park, KA
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
mi
from
Overland Park, KA
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
mi
from
Louisville, KY
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
mi
from
Baltimore, MD
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
mi
from
Rochester, MN
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
mi
from
Rochester, MN
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
mi
from
Jackson, MS
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
mi
from
Jackson, MS
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
mi
from
St. Joseph, MO
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
mi
from
St. Joseph, MO
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
mi
from
Henderson, NV
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
mi
from
Henderson, NV
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
mi
from
Lebanon, NH
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
mi
from
Lebanon, NH
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
mi
from
Newark, NJ
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
mi
from
Newark, NJ
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
mi
from
New York, NY
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
mi
from
Ashville, NC
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
mi
from
Ashville, NC
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
mi
from
Cleveland, OH
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
mi
from
Tulsa, OK
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
mi
from
Tulsa, OK
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
mi
from
Philadelphia, PA
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
mi
from
Charleston, SC
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
mi
from
Chattanooga, TN
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
mi
from
Dallas, TX
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
mi
from
Norfolk, VA
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
mi
from
Seattle, WA
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
mi
from
Milwaukee, WI
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
mi
from
Milwaukee, WI
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Mobile Diagnostic Center Rheumatology
mi
from
Mobile, AL
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Mobile Diagnostic Center Rheumatology
mi
from
Mobile, AL
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Valerius Medical Group
mi
from
Long Beach, CA
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Valerius Medical Group
mi
from
Long Beach, CA
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Trial Concierge/Pacific Clinical Studies
mi
from
Los Alamitos, CA
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Trial Concierge/Pacific Clinical Studies
mi
from
Los Alamitos, CA
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Axis Clinical Trials
mi
from
Los Angeles, CA
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Axis Clinical Trials
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Riverside Clinical Research
mi
from
Edgewater, FL
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Riverside Clinical Research
mi
from
Edgewater, FL
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Global Clinical Professionals
mi
from
Miami, FL
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Global Clinical Professionals
mi
from
Miami, FL
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
The Arthritis Center
mi
from
Palm Harbor, FL
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
The Arthritis Center
mi
from
Palm Harbor, FL
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Lakeview Medical Research
mi
from
Summerfield, FL
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Lakeview Medical Research
mi
from
Summerfield, FL
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Analan Clinical Research
mi
from
Lenexa, KA
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Analan Clinical Research
mi
from
Lenexa, KA
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Trial Concierge
mi
from
Owensboro, KY
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Trial Concierge
mi
from
Owensboro, KY
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Quality Clinical Research, Inc.
mi
from
Omaha, NE
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Quality Clinical Research, Inc.
mi
from
Omaha, NE
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Advanced Biomedical Research of America
mi
from
Las Vegas, NV
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Advanced Biomedical Research of America
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Arthritis Center of Reno
mi
from
Reno, NV
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Arthritis Center of Reno
mi
from
Reno, NV
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Pmg Research Of Salisbury
mi
from
Salisbury, NC
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Pmg Research Of Salisbury
mi
from
Salisbury, NC
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Providence Health Partners
mi
from
Dayton, OH
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Providence Health Partners
mi
from
Dayton, OH
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Paramount Medical Research & Consulting, Llc
mi
from
Middleburg Heights, OH
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Paramount Medical Research & Consulting, Llc
mi
from
Middleburg Heights, OH
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
The Center for Excellence in Aging and Geriatric Health
mi
from
Williamsburg, VA
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
The Center for Excellence in Aging and Geriatric Health
mi
from
Williamsburg, VA
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Apex Clinical Research
mi
from
Kennewick, WA
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Apex Clinical Research
mi
from
Kennewick, WA
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
South Puget Sound Clinical Research Center
mi
from
Olympia, WA
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
South Puget Sound Clinical Research Center
mi
from
Olympia, WA
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated:  11/15/2012
Clinical Research Facility
mi
from
Birmingham, AL
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated: 11/15/2012
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated:  11/15/2012
Clinical Research Facility
mi
from
Phoenix, AZ
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated: 11/15/2012
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated:  11/15/2012
Clinical Research Facility
mi
from
Santa Clara, CA
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated: 11/15/2012
Clinical Research Facility
mi
from
Santa Clara, CA
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated:  11/15/2012
Clinical Research Facility
mi
from
Bridgeport, CT
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated: 11/15/2012
Clinical Research Facility
mi
from
Bridgeport, CT
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated:  11/15/2012
Clinical Research Facility
mi
from
Newark, DE
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated: 11/15/2012
Clinical Research Facility
mi
from
Newark, DE
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated:  11/15/2012
Clinical Research Facility
mi
from
Daytona Beach, FL
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated: 11/15/2012
Clinical Research Facility
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated:  11/15/2012
Clinical Research Facility
mi
from
Decatur, GA
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated: 11/15/2012
Clinical Research Facility
mi
from
Decatur, GA
Click here to add this to my saved trials